Perform Another (Advanced) Search

1.  Newly Approved Drug Therapies (848) Spiriva HandiHaler (tiotropium bromide), Boehringer Ingelheim,
...Newly Approved Drug Therapies (848) Spiriva HandiHaler (tiotropium bromide), Boehringer Ingelheim, Drug Information The following information is obtained from various newswires, published medical journal articles, and medical conference presentations. Drug Name: Spiriva HandiHaler (tiotropium bromide) Company: Boehringer Ingelheim Approval Status: Approved February 2004 Treatment Area: Chronic Obstructive Pulmonary Disease ...
View Page

2.  Study Posting (1570) Trial #156495, Cystic Fibrosis, Morristown, NJ
...Morristown, NJ Trial Information Safety and Efficacy of 12-wk Treatment With Two Doses of Tiotropium Respimat in Cystic Fibrosis This study evaluates the effects of 12-week treatment with two doses of tiotropium bromide (2.5 mcg q.d. and 5 mcg q.d.) compared to placebo administered ...
View Page

3.  Study Posting (799) Trial #160044, Asthma, Boston, MA
...Study Posting (799) Trial #160044, Asthma, Boston, MA Trial Information Tiotropium Bromide as an Alternative to Increased Inhaled Corticosteroid in Patients Inadequately Controlled on a Lower ...
...Center, and the compensation is up to $1970. Study is designed to determine whether adding tiotropium bromide is superior to doubling the dose of an inhaled corticosteroid. All study medication will ...
View Page

4.  Study Posting (799) Trial #157727, Asthma, Boston, MA
...Study Posting (799) Trial #157727, Asthma, Boston, MA Trial Information Tiotropium Bromide as an Alternative to Increased Inhaled Corticosteroid in Patients Inadequately Controlled on a Lower ...
...Center, and the compensation is up to $1970. Study is designed to determine whether adding tiotropium bromide is superior to doubling the dose of an inhaled corticosteroid. All study medication will ...
View Page

5.  Study Posting (5031) Trial #156053, COPD (Chronic Obstructive Pulmonary Disease), Various Cities, VA
...investigative drug indacaterol is more effective at treating symptoms of moderate to severe COPD than tiotropium (Spiriva®, a drug co-marketed by Boehringer-Ingelheim and Pfizer). An ?investigational drug? is a ...
...Administration (FDA). Eligible participants will be asked to inhale either the investigative drug indacaterol, or tiotropium (Spiriva®) once a day over a 12-week period. For more information about this clinical ...
View Page

6.  Study Posting (5031) Trial #156052, COPD (Chronic Obstructive Pulmonary Disease), Various Cities, TX
...investigative drug indacaterol is more effective at treating symptoms of moderate to severe COPD than tiotropium (Spiriva®, a drug co-marketed by Boehringer-Ingelheim and Pfizer). An ?investigational drug? is a ...
...Administration (FDA). Eligible participants will be asked to inhale either the investigative drug indacaterol, or tiotropium (Spiriva®) once a day over a 12-week period. For more information about this clinical ...
View Page

7.  Study Posting (5031) Trial #156051, COPD (Chronic Obstructive Pulmonary Disease), Various Cities, OR
...investigative drug indacaterol is more effective at treating symptoms of moderate to severe COPD than tiotropium (Spiriva®, a drug co-marketed by Boehringer-Ingelheim and Pfizer). An ?investigational drug? is a ...
...Administration (FDA). Eligible participants will be asked to inhale either the investigative drug indacaterol, or tiotropium (Spiriva®) once a day over a 12-week period. For more information about this clinical ...
View Page

8.  Study Posting (5031) Trial #156050, COPD (Chronic Obstructive Pulmonary Disease), Various Cities, OH
...investigative drug indacaterol is more effective at treating symptoms of moderate to severe COPD than tiotropium (Spiriva®, a drug co-marketed by Boehringer-Ingelheim and Pfizer). An ?investigational drug? is a ...
...Administration (FDA). Eligible participants will be asked to inhale either the investigative drug indacaterol, or tiotropium (Spiriva®) once a day over a 12-week period. For more information about this clinical ...
View Page

9.  Study Posting (5031) Trial #156047, COPD (Chronic Obstructive Pulmonary Disease), Various Cities, NC
...investigative drug indacaterol is more effective at treating symptoms of moderate to severe COPD than tiotropium (Spiriva®, a drug co-marketed by Boehringer-Ingelheim and Pfizer). An ?investigational drug? is a ...
...Administration (FDA). Eligible participants will be asked to inhale either the investigative drug indacaterol, or tiotropium (Spiriva®) once a day over a 12-week period. For more information about this clinical ...
View Page

10.  Study Posting (5031) Trial #156049, COPD (Chronic Obstructive Pulmonary Disease), Various Cities, NY
...investigative drug indacaterol is more effective at treating symptoms of moderate to severe COPD than tiotropium (Spiriva®, a drug co-marketed by Boehringer-Ingelheim and Pfizer). An ?investigational drug? is a ...
...Administration (FDA). Eligible participants will be asked to inhale either the investigative drug indacaterol, or tiotropium (Spiriva®) once a day over a 12-week period. For more information about this clinical ...
View Page

11.  Study Posting (5031) Trial #156048, COPD (Chronic Obstructive Pulmonary Disease), Various Cities, NE
...investigative drug indacaterol is more effective at treating symptoms of moderate to severe COPD than tiotropium (Spiriva®, a drug co-marketed by Boehringer-Ingelheim and Pfizer). An ?investigational drug? is a ...
...Administration (FDA). Eligible participants will be asked to inhale either the investigative drug indacaterol, or tiotropium (Spiriva®) once a day over a 12-week period. For more information about this clinical ...
View Page

12.  Study Posting (5031) Trial #156046, COPD (Chronic Obstructive Pulmonary Disease), Various Cities, MO
...investigative drug indacaterol is more effective at treating symptoms of moderate to severe COPD than tiotropium (Spiriva®, a drug co-marketed by Boehringer-Ingelheim and Pfizer). An ?investigational drug? is a ...
...Administration (FDA). Eligible participants will be asked to inhale either the investigative drug indacaterol, or tiotropium (Spiriva®) once a day over a 12-week period. For more information about this clinical ...
View Page

13.  Study Posting (5031) Trial #156045, COPD (Chronic Obstructive Pulmonary Disease), Various Cities, MI
...investigative drug indacaterol is more effective at treating symptoms of moderate to severe COPD than tiotropium (Spiriva®, a drug co-marketed by Boehringer-Ingelheim and Pfizer). An ?investigational drug? is a ...
...Administration (FDA). Eligible participants will be asked to inhale either the investigative drug indacaterol, or tiotropium (Spiriva®) once a day over a 12-week period. For more information about this clinical ...
View Page

14.  Study Posting (5031) Trial #156044, COPD (Chronic Obstructive Pulmonary Disease), Various Cities, LA
...investigative drug indacaterol is more effective at treating symptoms of moderate to severe COPD than tiotropium (Spiriva®, a drug co-marketed by Boehringer-Ingelheim and Pfizer). An ?investigational drug? is a ...
...Administration (FDA). Eligible participants will be asked to inhale either the investigative drug indacaterol, or tiotropium (Spiriva®) once a day over a 12-week period. For more information about this clinical ...
View Page

15.  Study Posting (5031) Trial #156043, COPD (Chronic Obstructive Pulmonary Disease), Various Cities, KS
...investigative drug indacaterol is more effective at treating symptoms of moderate to severe COPD than tiotropium (Spiriva®, a drug co-marketed by Boehringer-Ingelheim and Pfizer). An ?investigational drug? is a ...
...Administration (FDA). Eligible participants will be asked to inhale either the investigative drug indacaterol, or tiotropium (Spiriva®) once a day over a 12-week period. For more information about this clinical ...
View Page

16.  Study Posting (5031) Trial #156042, COPD (Chronic Obstructive Pulmonary Disease), Various Cities, IN
...investigative drug indacaterol is more effective at treating symptoms of moderate to severe COPD than tiotropium (Spiriva®, a drug co-marketed by Boehringer-Ingelheim and Pfizer). An ?investigational drug? is a ...
...Administration (FDA). Eligible participants will be asked to inhale either the investigative drug indacaterol, or tiotropium (Spiriva®) once a day over a 12-week period. For more information about this clinical ...
View Page

17.  Study Posting (5031) Trial #156041, COPD (Chronic Obstructive Pulmonary Disease), Various Cities, IL
...investigative drug indacaterol is more effective at treating symptoms of moderate to severe COPD than tiotropium (Spiriva®, a drug co-marketed by Boehringer-Ingelheim and Pfizer). An ?investigational drug? is a ...
...Administration (FDA). Eligible participants will be asked to inhale either the investigative drug indacaterol, or tiotropium (Spiriva®) once a day over a 12-week period. For more information about this clinical ...
View Page

18.  Study Posting (5031) Trial #156040, COPD (Chronic Obstructive Pulmonary Disease), Various Cities, GA
...investigative drug indacaterol is more effective at treating symptoms of moderate to severe COPD than tiotropium (Spiriva®, a drug co-marketed by Boehringer-Ingelheim and Pfizer). An ?investigational drug? is a ...
...Administration (FDA). Eligible participants will be asked to inhale either the investigative drug indacaterol, or tiotropium (Spiriva®) once a day over a 12-week period. For more information about this clinical ...
View Page

19.  Study Posting (5031) Trial #156039, COPD (Chronic Obstructive Pulmonary Disease), Various Cities, FL
...investigative drug indacaterol is more effective at treating symptoms of moderate to severe COPD than tiotropium (Spiriva®, a drug co-marketed by Boehringer-Ingelheim and Pfizer). An ?investigational drug? is a ...
...Administration (FDA). Eligible participants will be asked to inhale either the investigative drug indacaterol, or tiotropium (Spiriva®) once a day over a 12-week period. For more information about this clinical ...
View Page

20.  Study Posting (5031) Trial #156038, COPD (Chronic Obstructive Pulmonary Disease), Various Cities, CO
...investigative drug indacaterol is more effective at treating symptoms of moderate to severe COPD than tiotropium (Spiriva®, a drug co-marketed by Boehringer-Ingelheim and Pfizer). An ?investigational drug? is a ...
...Administration (FDA). Eligible participants will be asked to inhale either the investigative drug indacaterol, or tiotropium (Spiriva®) once a day over a 12-week period. For more information about this clinical ...
View Page